# Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

> **NCT05418010** · PHASE2 · RECRUITING · sponsor: **Queen Mary University of London** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Sclerosis
- Clinically Isolated Syndrome of Demyelination

## Interventions

- **DRUG:** Tyruko Injectable Product
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05418010
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05418010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05418010, "Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05418010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*